EnzyCeuticals offers engineered PHA depolymerases that enable closed-loop enzymatic recycling of polyhydroxyalkanoate bioplastics. These robust enzymes depolymerize PHA waste into reusable monomers, supporting a circular plastics economy without quality loss, unlike conventional thermomechanical recycling.
EnzyCeuticals has developed a portfolio of novel PHA depolymerases designed for the enzymatic recycling of biodegradable bioplastics such as polyhydroxyalkanoates (PHAs). Unlike conventional thermomechanical recycling, which is limited to clean plastics and degrades material quality with each cycle, enzymatic depolymerization enables the recovery of high-quality monomers from complex, soiled, or mixed PHA waste streams. This approach supports a true circular plastics economy by allowing recycled PHA to be reprocessed into new, fully recyclable products without loss of performance. The enzymes were discovered through genome-based computational mining and metagenomics screening of extreme thermal springs, then enhanced via protein engineering for industrial robustness.
Key features:
The PHA depolymerases have been experimentally validated at lab scale, with best-performing enzyme variants identified and characterized for structural stability and catalytic activity. Current and planned next steps include optimizing pilot-scale enzyme production and extraction, scaling up PHB depolymerization of packaging and fiber waste, computational modeling of polymer–enzyme interactions, and integrated fermentation of hydrolyzed media into value-added PHA copolymers. The technology is advancing from lab-scale validation toward pilot-scale demonstration.
EnzyCeuticals is a biotechnology company founded in 2021 as a spin-off from the Agricultural University of Athens. The company specializes in the development and manufacture of innovative, high-quality enzymes and enzyme-based products for the food, health, and cosmetic industries. They utilize their proprietary iEζC platform technology, which integrates omics, bioinformatics, artificial intelligence, synthetic biotechnology, and protein engineering to accelerate enzyme discovery and design. Their offerings include a diverse portfolio of recombinant and native enzymes, proprietary Xenobody protein libraries, and affinity adsorbents, with production maintained under ISO 9001 standards.
These solutions enable customers across various sectors to implement sustainable enzymatic processes. By leveraging their cross-disciplinary expertise, EnzyCeuticals provides novel candidates for applications such as biosensing, bioscavenging, biocatalysis, and drug delivery. The company is recognized as an official member of the Greek startup ecosystem, Elevate Greece, and focuses on developing safe, sustainable, and financially viable enzyme technologies to drive the enzyme bioeconomy. Their work supports both R&D initiatives and industrial-scale requirements, helping partners optimize their operations through advanced biotechnological routes.